"Urinary excretion plays an important role in the elimination of dexrazoxane. Forty-two percent of the 500 mg/m2 dose of dexrazoxane was excreted in the urine."@en . . "Humans and other mammals"@en . "(+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane"@en . "Dexrazoxane"@en . " "@en . . . "Intraperitoneal, mouse LD₁₀ = 500 mg/kg. Intravenous, dog LD₁₀ = 2 gm/kg."@en . . . "(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione"@en . . . "# Hasinoff BB, Herman EH: Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc Toxicol. 2007;7(2):140-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17652819 # Hasinoff BB: The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Investig Drugs. 2008 Feb;17(2):217-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18230055 # Kik K, Szmigiero L: [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs] Postepy Hig Med Dosw (Online). 2006;60:584-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17115008 # Weiss G, Loyevsky M, Gordeuk VR: Dexrazoxane (ICRF-187). Gen Pharmacol. 1999 Jan;32(1):155-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9888268 # Langer SW: Dexrazoxane for anthracycline extravasation. Expert Rev Anticancer Ther. 2007 Aug;7(8):1081-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18028016"@en . . . "approved"@en . . . . . . . . . . . "For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines."@en . . . "24584-09-6"@en . . . . "Very low (< 2%)"@en . "Dexrazoxane"@en . . . . . . . "* 7.88 L/h/m2 [dose of 50 mg/m2 Doxorubicin and 500 mg/m2 Dexrazoxane] * 6.25 L/h/m2 [dose of 60 mg/m2 Doxorubicin and 600 mg/m2 Dexrazoxane]"@en . . . . . . . . . . "* 9 to 22.6 L/m^2"@en . . . . "Dextrorazoxane"@en . . . . . . . . . . . . "Dexrazoxano"@en . " "@en . . . "Dexrazoxan"@en . . . . . . . . "An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy."@en . "IV administration results in complete bioavailability."@en . "withdrawn"@en . "2.5 hours"@en . . "4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione"@en . . "Dexrazoxanum"@en . . "The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane (a prodrug) is converted intracellularly to a ring-opened bidentate chelating agent that chelates to free iron and interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. It should be noted that dexrazoxane may also be protective through its inhibitory effect on topoisomerase II."@en .